Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
A phase 1/2 trial of Lurbinectedin in ewing sarcoma, run by Jazz Pharmaceuticals, now recruiting.
Overview
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma is a phase 1/2 interventional study registered as NCT05734066 by Jazz Pharmaceuticals, with 60 participants planned, started 2023-05-23 and due to reach its primary completion in 2028-01-28. Interventions recorded: Lurbinectedin. Conditions listed: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma.
Phase
Phase 1/2
Sponsor
Jazz Pharmaceuticals
Registry
Enrolled
60